A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Advanced Cancer
Interventions: BIOLOGICAL: Nivolumab|BIOLOGICAL: Daratumumab
Sponsor: Bristol-Myers Squibb
Collaborators: Janssen Biotech, Inc.